Latest Comments on EP Vantage's Articles

1. xicasicooi on Teva Deal a Reality Check for OncoGenex Investors : sorry to disturb u. just take u a little time. If you are in... more »
2. E Nuff Sed on Sanofi-Aventis Going OTC with Chattem Buy: Don't know where you got the sales data from but it is way off. ... more »
3. E Nuff Sed on Sanofi-Aventis Going OTC with Chattem Buy: Smart move. The market is paying much higher P/E multiples for... more »
4. Furd Turgeson on Facet Rebuffs Biogen: Will a White Knight Emerge?: Good balanced look at FACT. While it seems that Biogen did try to... more »
5. sierranvin on High Hopes Remain for Celgene's Revlimid: yeah, like your one patient anecdote adds something to a... more »
6. daphne doesn't believe on High Hopes Remain for Celgene's Revlimid: yeah, my sister ended up in the emergency room in february with a... more »
7. Vobogeck on Merck KGaA: Another Stumble Leaves Investors Worried: Merck KGaA, which trades on the DAX, is an unrelated entity to... more »
8. Pierr Johnson on Genzyme's Very Bad Year: Kudos for the insights. Still, it is important to point out the... more »
9. frosty on Genzyme's Very Bad Year: Mr. Icahn is interested only in turning a fast buck. People like... more »
10. San Juan on Genzyme's Very Bad Year: The article highlights all the known information that has produced... more »
11. Justin M. Hall on Genzyme's Very Bad Year: Regarding Icahn, check out Biogen Idec (BIIB) mid-2007. As I... more »
12. stockinvestor on Genzyme's Very Bad Year: I agree with the facts that you provide in your article, but I... more »
13. InvestmentGuru on Poniard Pharmaceuticals' Gamble Doesn't Pay Off: CEO JM is a gambler and should be put behind bars for not... more »
14. Justin M. Hall on NeurogesX: Next Stop, U.S. Market: EP: Thank you for the heads up on NGSX. Justin more »
15. jay brebner on Poniard Pharmaceuticals' Gamble Doesn't Pay Off: spear was a very risky trial given the way it was designed. their... more »